Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma

Journal of Clinical Oncology

Volumn 16, Issue 2, 1998, Pages 683-691

  Stewart, Simon ^a   Jablonowski, Helmut ^b   Goebel, Franc D ^b   Arasteh, Keikawus ^b   Spittle, Margaret ^b   Rios, Adan ^b   Aboulafia, David ^b   Galleshaw, Janice ^b   Dezube, Bruce J ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; DOXORUBICIN; VINCRISTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0031941991     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.2.683     Document Type: Article

References (28)

1. Beral V: The epidemiology of cancer in AIDS patients. AIDS 5:599-603, 1991 (suppl 2)
2. Reynolds P, Saunders LD, Layefsky ME, et al: The spectrum of acquired immunodeficiency syndrome (AIDS)-associated malignancies in San Francisco, 1980-1987. Am J Epidemiol 137:19-30, 1993
3. Caumes E, Guermonprez G, Katlama C, et al: AIDS-associated mucocutaneous Kaposi's sarcoma treated with bleomycin. AIDS 6:1483-1487, 1992
4. Fischl MA, Krown SE, O'Boyle KP, et al: Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi's sarcoma. AIDS Clinical Trials Group. J Acquir Immune Defic Syndr 6:259-264, 1993
5. Kaplan L, Abrams D, Volberding P: Treatment of Kaposi's sarcoma in acquired immunodeficiency syndrome with an alternating vincristine-vinblastine regimen. Cancer Treat Rep 70:1121-1122, 1986
6. Shepherd FA, Burkes RL, Paul KE, et al: A phase II study of 4′-epirubicin in the treatment of poor-risk Kaposi's sarcoma and AIDS. AIDS 5:305-309, 1991
7. Gompels MM, Hill A, Jenkins P, et al: Kaposi's sarcoma in HIV infection treated with vincristine and bleomycin. AIDS 6:1175-1180, 1992
8. Gill PS, Rarick MU, Berstein-Singer M: Treatment of advanced stage Kaposi's sarcoma using a combination of bleomycin and vincristine. Am J Oncol 13:315-319, 1990
9. Gill PS, Miles SA, Mitsuyasu RT, et al: Phase 1 AIDS Clinical Trials Group (075) study of adriamycin, bleomycin and vincristine chemotherapy with zidovudine in the treatment of AIDS-related Kaposi's sarcoma. AIDS 8:1695-1699, 1994
10. Laubenstein LJ, Krigel RL, Odajnyk CM, et al: Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine, J Clin Oncol 2:1115-1120, 1984
11. Simpson JK, Miller RF, Spittle MF: Liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma. Clin Oncol 5:372-377, 1993
12. Harrison M, Tomlinson ND, Stewart S: Liposomal entrapped doxorubicin: An active agent in AIDS-related Kaposi's sarcoma. J Clin Oncol 13:914-920, 1995
13. Bogner JR, Kronawitter U, Rolinski B, et al: Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi's sarcoma. J AIDS 7:463-468, 1994
14. Gill PS, Espina BM, Muggia F, et al: Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol 13:996-1003, 1995
15. Money-Kyrle JF, Bates F, Ready J, et al: Liposomal daunorubicin in advanced Kaposi's sarcoma: A phase II study. Clin Oncol 5:367-371, 1993
16. Schurmann D, Dormann A, Grunewald T, et al: Successful treatment of AIDS-related pulmonary Kaposi's sarcoma with liposomal daunorubicin. Eur Respir J 7:824-825, 1994
17. Klibanov AL, Maruyama K, Torchilin VP, et al: Amphipathic polyethylene-glycols effectively prolong the circulation times of liposomes. FEBS Lett 268:235-237, 1990
18. Huang SK, Mayhew E, Giliani S, et al: Pharmacokinetics and therapeutics of sterically stabilised liposomes in mice bearing C 26 colon carcinoma. Cancer Res 52:6774-6781, 1992
19. Northfelt DW, Martin FJ, Working P, et al: Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: Pharmacokinetics, tumour localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 36:55-63, 1996
20. Krown SE, Metroka C, Wernz JC, for the AIDS Clinical Trials Group Oncology Committee: Kaposi's sarcoma in the acquired immunodeficiency syndrome: A proposal for uniform evaluation, response and staging criteria. AIDS Clinical Trials Oncology Committee. J Clin Oncol 7:1201-1207, 1989
21. COSTART: Coding Symbols for Thesaurus of Adverse Reaction Terms. Rockville, MD, Report No Food and Drug Administration FDA/CDER-95/24
22. Agresti A: Chapter 8, in Categorical Data Analysis. Wiley, 1990
23. Kaplan LD, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
24. Krown SE, Myskowski PL, Paredes J: Medical management of AIDS patients: Kaposi's sarcoma. Med Clin North Am 76:235-252, 1992
25. Northfelt DW, Dezube B, Miller B, et al: Randomized comparative trial of pegylated liposomal doxorubicin vs adriamycin, bleomycin and vincristine (ABV) in the treatment of severe AIDS-related Kaposi's sarcoma (AIDS-KS). Blood 86 10:382a, 1995 (suppl 1)
26. Gill PS, Wernz J, Scadden DT, et al: Randomized phase III study of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 14:2353-2364, 1996
27. Berry G, Billingham M, Alderman E, et al: Reduced cardiotoxicity of pegylated liposomal doxorubicin in AIDS Kaposi's sarcoma patients compared to a matched control group of cancer patients given doxorubicin. Proc Am Soc Clin Oncol 15, 1996 (abstr 843)
28. Uziely B, Jeffers S, Isacson R, et al: Liposomal doxorubicin: Antitumour activity and unique toxicities during two complementary phase I studies. J Clin Oncol 13:1777-1785, 1995